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Gastric emptying is a complex process, one that is highly variable and that makes in vivo performance 
of drug delivery systems uncertain. A controlled drug delivery system with prolonged residence time 
in the stomach can be of great practical importance for drugs with an absorption window in the upper 
small intestine. The main limitations are attributed to the inter- and intra-subject variability of gastro-
intestinal (GI) transit time and to the non-uniformity of drug absorption throughout the alimentary 
canal. Floating or hydrodynamically controlled drug delivery systems are useful in such applications. 
Various gastroretentive dosage forms are available, including tablets, capsules, pills, laminated films, 
floating microspheres, granules and powders. Floating microspheres have been gaining attention due 
to the uniform distribution of these multiple-unit dosage forms in the stomach, which results in more 
reproducible drug absorption and reduced risk of local irritation. Such systems have more advantages 
over the single-unit dosage forms. The present review briefly addresses the physiology of the gastric 
emptying process with respect to floating drug delivery systems. The purpose of this review is to bring 
together the recent literature with respect to the method of preparation, and various parameters affecting 
the performance and characterization of floating microspheres. 
Uniterms: Floating microspheres. Emulsion solvent diffusion-evaporation method. Drug delivery 
system. Release modifiers.
O esvaziamento gástrico é um processo complexo, com elevada variabilidade e responsável pela incerteza 
do desempenho dos medicamentos in vivo. Dessa forma, os sistemas de liberação modificada de fármacos, 
com tempo de residência prolongado no estômago, em especial, considerando aqueles fármacos com 
janela de absorção na porção superior do intestino delgado, apresentam fundamental importância. As 
principais limitações relativas à absorção do fármaco são, no geral, atribuídas à variabilidade inter e 
intra-paciente do tempo de trânsito gastro-intestinal (GI) e da não-uniformidade da absorção do fármaco 
na extensão do canal alimentar. Assim, justifica-se a utilização dos sistemas flutuantes ou hidrodinâmicos 
de liberação de fármacos. Vários medicamentos gastrorretentivos estão disponibilizados no mercado 
e incluem comprimidos, cápsulas, pílulas, filmes laminados, microesferas flutuantes, grânulos e pós. 
As microesferas flutuantes apresentam maior destaque em função da distribuição granulométrica 
uniforme dessas formulações de dose múltipla. Como resultado, a absorção do fármaco apresenta maior 
reprodutibilidade e os riscos associados à irritação local são reduzidos. Tais sistemas apresentam maior 
vantagem quando comparado às formulações de dose única. A presente revisão tem como objetivo 
apresentar as publicações recentes referentes aos métodos de preparação, os vários parâmetros que 
afetam o desempenho e a caracterização das microesferas flutuantes. Além disso, o presente trabalho 
aborda a fisiologia do processo de esvaziamento gástrico no que se refere aos sistemas flutuantes de 
liberação de fármacos.
Unitermos: Microesferas flutuantes. Método solvente da difusão-evaporação. Fármacos/liberação 
controlada. Modificadores de liberação.
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INTRODUCTION
Among the different routes of drug administration, 
the oral route has achieved the most attention, partly due 
to the ease of administration and to the important flex-
ibility in dosage form design (Soppimath et al., 2001). 
Unfortunately, in most cases, the important variability of 
the gastrointestinal tract physiology and of its transit time 
leads to unpredictable bioavailability and non reproducible 
therapeutic effects. One requisite for the successful perfor-
mance of oral controlled release drug delivery systems is 
that the drug should have good absorption throughout the 
gastrointestinal tract (GIT), preferably by passive diffusion 
(Patil et al., 2006).
Most drugs are well absorbed throughout the entire 
intestinal tract, but some compounds, usually those that are 
polar in nature, are poorly absorbed from the large intes-
tine. For such drugs, the main area from which absorption 
occurs is the small intestine. Some drugs may exploit a 
natural pathway, such as receptor-mediated transport, ac-
tive transport or other specific transport mechanisms, and 
are known to have so-called “absorption windows” in the 
small intestine. Gastric emptying of dosage forms is an 
extremely variable process and the ability to prolong and 
control emptying time is a valuable asset for dosage forms 
that reside in the stomach for a longer period of time than 
conventional dosage forms (Shweta et al., 2005).
Several difficulties are faced in designing controlled 
release systems for better absorption and enhanced bio-
availability. One of such difficulties is the inability to con-
fine the dosage form in the desired area of the gastrointes-
tinal tract. Drug absorption from the gastrointestinal tract 
is a complex procedure and is subject to many variables. It 
is widely acknowledged that the extent of gastrointestinal 
tract drug absorption is associated with time of contact 
with the small intestinal mucosa (Hirtz, 1985).
Gastroretentive systems can remain in the gastric 
region for several hours and hence significantly prolong 
the gastric residence time of drugs. Prolongation of gas-
tric residence time (GRT) of a rate-controlled oral drug 
delivery system reduces inter-subject variability and the 
so-called “peak and valley” effect, leading to increased 
predictability and bioavailability of the dosage form, 
especially for molecules with a narrow absorption win-
dow. Moreover, the total gastrointestinal transit time is 
prolonged, thus, the number of dosage regimen can be 
reduced and solubility can be improved for drugs that are 
less soluble in a high pH environment.
The development of gastroretentive dosage forms 
capable of staying in the stomach over an extended period 
of time may be particularly useful for drugs that may act 
locally in the stomach, e.g., antacids, antibiotics for ulcers 
of bacterial origin (Franz, Oth, 1993); drugs that are ab-
sorbed primarily in the stomach, e.g., albuterol, chlordiz-
epoxide (Sheth, Tossounian, 1978); drugs that absorbed 
rapidly from the GI tract, e.g., amoxicillin (Hilton, Deasy, 
1992); drugs that have a narrow absorption window and 
are (mainly) absorbed from the upper small intestine, e.g., 
ofloxacin, levodopa, riboflavin, theophylline (Avachat, 
Dhamne, 2002; Sheth, Tossounian, 1979; Desai, Boltan, 
1989); drugs having low bioavailability and drugs that 
degrade in the colon, e.g., ranitidine, metoprolol (Dave, 
Amin, Patel, 2004); and drugs that are poorly soluble in 
intestinal pH, e.g., diazepam, weak bases such as dipyri-
damole (Hoffmann, 1979).
The controlled gastric retention of solid dosage 
forms may be achieved by the mechanisms of mucoadhe-
sion (Ponchel, Irache, 1998; Gupta, Sau-Hung, Robinson, 
1990), floatation (Deshpande et al., 1997), sedimentation 
(Rednick, Tucker, 1970; Davis et al., 1986), expansion 
(Urguhart, Theeuws, 1994; Mamajek, Moyer, 1980), mod-
ified shape systems (Fix, Cargill, Engle, 1993; Kedziere-
wicz et al., 1999), or by the simultaneous administration of 
pharmacological agents (Groning, Heun, 1984; Groning, 
Heun, 1989); that delay gastric emptying.
Some excipients, such as glycerol monooleate ma-
trix (Paradkar et al., 2004) and Gelucire® (Chauhan et 
al., 2004), were also found to be gastro-retentive carrier 
systems, suitable for both polar and non-polar drugs.
Most of the floating systems reported in literature 
are single-unit systems, which are generally unreliable 
and non-reproducible in prolonging the GRT, in virtue 
of their unpredictable all-or-nothing emptying process. 
On the other hand, multiple-unit dosage forms appear to 
be better suited, since they claim to reduce inter-subject 
variability in absorption and have a lower dose-dumping 
probability (Singh, Kwon, 2000). The uniform distribution 
of these multiple unit dosage forms along the GIT could 
result in more reproducible drug absorption and reduced 
risk of local irritation; this gave way to the development 
of gastroretentive floating microspheres.
Floating microspheres are gastroretentive drug 
delivery systems based on a non-effervescent approach. 
Hollow microspheres, microballoons or floating mic-
roparticles are terms used synonymously for floating 
microspheres. Floating microspheres are, in a strict sense, 
spherical empty particles without a core. These are free-
flowing particles, with size ranging from 1 to 1000 µm. 
Kawashima et al. (1992) have developed non-effervescent 
hollow polycarbonate microspheres by using an emulsion 
solvent evaporation method. This gastrointestinal transit-
controlled preparation is designed to float on gastric juice 
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with a specific density of less than one. This property 
results in delayed transit through the stomach. The drug 
is released slowly at desired rate, resulting in increased 
gastric retention with reduced fluctuations in plasma 
drug concentration. The objective of the present review 
is to focus on the method of preparation, and the various 
parameters affecting the performance and characterization 
of floating microspheres. The present review is a source of 
detailed information about the various aspects of floating 
microspheres.
Basic gastrointestinal tract physiology
Anatomically, the stomach is divided into three re-
gions: fundus, body, and antrum (pylorus). The proximal 
part made of fundus and body acts as a reservoir for un-
digested material, whereas the antrum is the main site for 
mixing motions and acts as a pump for gastric emptying, 
through propelling actions. Gastric emptying occurs dur-
ing fasting as well as in fed states. The pattern of motility 
is, however, distinct in the two states. During the fasting 
state, an interdigestive series of electrical events takes 
place, cycling through both stomach and intestine every 
two to three hours. This is called the interdigestive my-
loelectric cycle or migrating myloelectric cycle (MMC), 
which is further divided into the following four phases, as 
described by Wilson and Washington (1989).
1. Phase I (basal phase) lasts from 40 to 60 minutes 
with rare contractions.
2. Phase II (preburst phase) lasts for 40 to 60 minutes 
with intermittent action potential and contractions. 
As the phase progresses, the intensity and frequency 
also increases gradually.
3. Phase III (burst phase) lasts for four to six minutes. It 
includes intense and regular contractions for a short 
period. It is due to this wave that all the undigested 
material is swept out of the stomach down to the 
small intestine. It is also known as the housekeeper 
wave.
4. Phase IV lasts for zero to five minutes and occurs 
between phases III and I of two consecutive cycles.
After the ingestion of a mixed meal, the pattern of 
contractions changes from fasted to that of fed state. This 
is also known as digestive motility pattern and comprises 
continuous contractions as in phase II of the fasted state. 
These contractions result in reduced size of food particles 
(to less than 1 mm), which are then propelled toward the 
pylorus in a suspension form. During the fed state, onset 
of MMC is delayed, resulting in slowdown of gastric 
emptying rate. Scintigraphic studies determining gastric 
emptying rates have revealed that orally administered 
controlled-release dosage forms are subject to basically 
two complications, namely short gastric residence time 
and unpredictable gastric emptying rate (Griffith et al., 
1996; Wilding, Coupe, Davis, 2001). Various other meth-
ods have also demonstrated the variation in gastric emp-
tying in humans under normal gravity conditions. Such 
methods include gastric aspiration (Maughan, Leiper, 
1996), ultrasound (Holt et al., 1985; Dietrich, Braden, 
2009), epigastric impedance (McClelland, Sutton, 1985), 
magnetic resonance imaging (MRI) techniques (Maughan, 
Leiper, 1996; Christmann et al., 1997), [13C]-octanoic acid 
breath test (Ghoos et al., 1993) and Pellet Gastric Empty-
ing Test (PGET) (Choe et al., 2001).
Factors affecting gastric retention
Gastric residence time of an oral dosage form is 
affected by several factors. In order to pass through the 
pyloric valve into the small intestine, particle size should 
be within the range of 1 to 2 mm (Wilson, Washington, 
1989). The pH of the stomach in fasting state is ~1.5 to 2.0 
and, in fed state, it is 2.0 to 6.0. A large volume of water 
administered with an oral dosage form raises the pH of 
stomach contents above 4. The stomach does not have 
time to produce sufficient acid when the liquid empties 
the stomach; hence, basic drugs generally have a better 
chance of dissolving in fed state than in fasting state. The 
rate of gastric emptying depends mainly on viscosity, 
volume and on the caloric content of meals. Nutritive 
density of meals helps determine gastric emptying time. 
It does not make any difference whether the meal has 
high protein, fat or carbohydrate content, as long as the 
caloric content is the same (Hunt, Stubbs, 1975; Calbet, 
Maclean, 1997). However, increase in acidity and caloric 
value slows down gastric emptying. Velehik, Reynolds and 
Alavi (1989) have studied the effect of meal energy over 
gastric content. They have found that the time required to 
empty the stomach to half of its initial content (T1/2) was 
57, 70 and 95 minutes for 150 kcal, 300 kcal and 600 kcal, 
respectively. Biological factors such as age, body mass in-
dex (BMI), gender, posture, and diseased states (Diabetes, 
Chron’s disease) influence gastric emptying. In the case 
of elderly persons, gastric emptying is also slowed down. 
Generally, females have slower gastric emptying rates than 
males. Stress increases the rate of gastric emptying, while 
depression slows it down. 
Alcohol and opioids reduce the rate of gastric 
empting, as do pain, fear, and anxiety (acting via the 
sympathetic nervous system which inhibits motility). Anti-
muscarinics, e.g., atropine, glycopyrrolate, also increase 
gastric emptying time. Metoclopramide, a prokinetic drug, 
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is a centrally and peripherally acting dopaminergic D2 
antagonist that increases the rate of gastric emptying and 
small intestinal transit, and also increases lower oesopha-
geal sphincter constriction. Domperidone has a similar 
pharmacological action as that of metoclopramide. The 
macrolide antibiotic erythromycin has prokinetic proper-
ties. It is an agonist at motilin receptors, stimulating strong 
antral contractions. Anti-cholinesterases, e.g., neostigmine 
decreases the gastric emptying time (Jolliffe, 2009).
The resting volume of the stomach is 25 to 50 mL. 
Volume of liquids administered affects gastric emptying 
time. When volume is large, emptying is faster. Fluids 
taken at body temperature leave the stomach faster than 
colder or warmer fluids. Studies have revealed that gas-
tric emptying of a dosage form in the fed state can also 
be influenced by its size. Small-sized tablets leave the 
stomach during the digestive phase, while the large-sized 
tablets are emptied during the housekeeping waves (Oth, 
Franz, Timmermans, 1992). The above data is again sup-
ported by the study carried out by Rhie et al. (1998). They 
have found smaller pellets (0.7 mm) emptying during fed 
state and larger pellets (3.6 mm) emptying during fasted 
state. Various gastric emptying times were observed for 
non-disintegrating tablets of different sizes. The longest 
gastric emptying time was observed for 13 mm tablets 
(171 ± 13 min), followed by 11 mm tablets (128 ± 17 min) 
and 7 mm tablets (116 ± 19 min) (Khosla, Davis, 1990).
It has been demonstrated, using radiolabeled tech-
nique, that there is a difference between gastric the emp-
tying times of a liquid, digestible solid, and indigestible 
solid. It was suggested that the emptying of large (91 mm) 
indigestible objects from the stomach was dependent upon 
interdigestive migrating myoelectric complex. When 
liquid and digestible solids are present in the stomach, 
it contracts ~3-4 times per minute, leading to the move-
ment of the contents through the partially opened pylorus. 
Indigestible solids larger than the pyloric opening are 
propelled back and several phases of myoelectric activ-
ity take place when the pyloric opening increases in size, 
during the housekeeping wave, and allows the sweeping 
of indigestible solids. 
Studies have shown that the gastric residence time 
can be significantly increased under the fed conditions, 
since the MMC is delayed (Mojaverian et al., 1985). 
Several formulation parameters can affect gastric resi-
dence time. More reliable gastric emptying patterns are 
observed for multiparticulate formulations, as compared 
to single-unit formulations, which suffer from the “all or 
none concept.” As the units of multiparticulate systems 
are distributed freely throughout the gastrointestinal tract, 
their transport is affected to a lesser extent by the transit 
time of food, when compared to single-unit formulations 
(Bechgaard, Ladefoged, 1978). Size and shape of dosage 
unit also affect gastric emptying. 
The density of a dosage form also affects the gastric 
emptying rate. A buoyant dosage form having a density of 
less than that of the gastric fluids will float. Since it is away 
from the pyloric sphincter, the dosage unit is retained in 
the stomach for a prolonged period. Posture and nature of 
the meal also have an effect on gastric emptying.
Advantages of floating microspheres:
1. Bioavailability enhances, despite first pass effect, 
because fluctuations in plasma drug concentration 
are avoided, and a desirable plasma drug concentra-
tion is maintained by continuous drug release.
2. Superior to single-unit floating dosage forms, as such 
microspheres release drugs uniformly and there is 
no risk of dose dumping.
3. Enhanced absorption of drugs that solubilise only in 
stomach.
4. Site-specific drug delivery to the stomach can be 
achieved.
5. Avoidance of gastric irritation, due to sustained 
release effect.
6. Better therapeutic effect of short half-life drugs can 
be achieved.
Reproducibility of the particle size of the formula-
tion is the main problem associated with floating micro-
spheres (Mitsutoshi et al., 2001).
METHODS OF PREPARATION OF HOLLOW 
MICROSPHERES
Hollow microspheres are prepared through the 
solvent diffusion and evaporation method to create the 
hollow inner core. The solvent is evaporated either by 
increasing the temperature under pressure or by continu-
ous stirring. 
Sato et al. (2004c) prepared the floating micro-
spheres by the emulsion solvent diffusion method, uti-
lizing enteric acrylic polymers dissolved with drug in 
a mixture of dichloromethane and ethanol. The above 
solution was introduced in the aqueous solution of poly-
vinyl alcohol at 40 ºC with constant stirring to form an 
oil-in-water (o/w) emulsion. After agitating the system for 
1 hour, the resulting polymeric particulate systems were 
sieved between 500 and 1000 mm and then dried overnight 
at 40 ºC to produce hollow microspheres.
Jain et al. (2005) used the emulsion solvent diffusion 
technique with a modification. The drug was adsorbed 
on a porous carrier (calcium silicate). The drug-adsorbed 
porous carrier was added into the polymer solution 
Floating microspheres: a review 21
(Eudragit S) in the mixture of ethanol and dichloromethane 
(2:1) and sonicated using a probe sonicator. The resulting 
suspension was poured into an aqueous solution of poly-
vinyl alcohol (0.75% w/v) at 40 ºC. The emulsion was 
stirred at 500 rpm employing a propeller-type agitator for 
3 hours. The microspheres were separated by filtration, 
washed with water and dried at room temperature in a 
desiccators for 24 hours.
Wei et al. (2008) prepared hollow microspheres by 
using liquid paraffin as an external phase. Microspheres 
possessing an internal hollow structure were prepared 
using an oil-in-oil (o/o) emulsion solvent diffusion-
evaporation method. Drug and polymer were dispersed or 
dissolved in ethanol by ultrasonication at room tempera-
ture, followed by addition of ether. Then a suspension of 
drug and polymer was slowly emulsified into an agitated 
external phase of liquid paraffin containing Span-80 as 
surfactant at 30 ºC. The dispersion system was stirred at 
a constant speed of 300 rpm for 8 hours. When evapora-
tion of solvents was complete, the hollow microspheres 
formed were separated by filtration, washed with n-hexane 
and dried in an air oven at 50 ºC for 12 hours before being 
stored in a desiccator.
Schmidt and Roessling (2006) developed a novel 
manufacturing process of gas-filled, hollow, poly-butyl-
2-cyanoacrylate (PBCA) microspheres in an aqueous 
phase. A novel two-step manufacturing process was 
developed to synthesize gas-filled hollow microspheres. 
This process is outlined in Figure 1. These microspheres 
have an organic shell. The first step is the polymeriza-
tion process of n-butyl-2- cyanoacrylate (BCA) to form 
nanoparticles. During the second step, the nanoparticles 
attach on a microbubble precursor and finally form hollow 
microspheres.
Mitsutoshi et al. (2001) had given the continuous 
manufacturing method for preparation of microspheres 
and the apparatus thereof. This invention provides a 
method for continuously manufacturing microspheres 
comprising the following steps: transferring a pressur-
ized dispersed phase into a continuous phase by force, 
via a plurality of microchannels having a predetermined 
width, in order to produce emulsions and withdrawing 
microspheres in the form of produced emulsions and fine 
particles suspended in liquid, etc., with the microspheres 
floating and sinking in response to their specific gravity.
Daniel, MacAusland and Baker (2011) have devel-
oped buoyant polymer particles for delivery of therapeutic 
agents to the central nervous system. The invention uses 
a biodegradable polymer composition containing a thera-
peutic agent, a polymer and a buoyancy agent. The given 
composition is controllably buoyant in cerebrospinal fluid. 
The degree of buoyancy is controlled by the various com-
binations and amounts of the buoyancy agent. The various 
buoyancy agents used with polymers are: mineral oil, 
isopropyl meristate, Labrifil 1944, vegetable oil, methyl 
oleate, lanoline, petrolatin, cetyl alcohol, corn oil, soybean 
oil, castor oil, air, nitrogen, argon, hydrofluorocarbons, 
carbondioxide, helium, and xenon.
Cellulose acetate, chitosan, Eudragit®, Acrycoat, 
Methocel, polyacrylates, polyvinyl acetate, Carbopol, 
agar, polyethylene oxide, polycarbonates, acrylic resins 
and polyethylene oxide are some of the polymers used in 
the preparation of hollow microspheres.
Mechanism of formation of hollow microspheres
Ethanol and methanol have been found to be good 
solvents for most drugs and polymers. Dichlorometh-
ane and chloroform are good bridging liquids due to 
the good linkage between the drug and polymers and to 
their immiscibility in the external phase. Water-insoluble 
polymers, mentioned above, show higher solubility in 
dichloromethane than ethanol. However, ethanol has 
higher solubility in water. As soon as the polymer solu-
tion was added to the aqueous medium, the ethanol dif-
fuses rapidly from the droplets of the polymer solution. 
Simultaneous diffusion of water inside the sphere further 
decreased the ethanol concentration, hence the polymer 
precipitated, resulting in the formation of microspheres. 
Dichloromethane remaining as the central core diffused 
slowly due to its low water solubility. Therefore, the dif-
fusion of ethanol played an important role in determining 
the size and shape of the microspheres. The diagrammatic 
representation of mechanism of formation of floating 
microspheres is given in the Figure 2. The inner porous 
FIGURE 1 - Scheme of the two-step process for the synthesis 
of gas-filled hollow microspheres (Schmidt, Roessling, 2006).
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structure was attributed to the inward diffusion of water, 
which resulted in the solidification of the polymer and the 
formation of several smaller pockets of dichloromethane 
rich entrapments which diffused out together with etha-
nol. The entrapped dichloromethane diffused slowly out 
of the pocket giving a porous structure to the wall of the 
microspheres (Figure 3b). Due to the poor miscibility, 
water could not effectively invade the dichloromethane 
rich core. Therefore, the diffusion of dichloromethane 
began late, after the initial solidification, and formed 
a central hollow structure. During the diffusion of the 
solvents, the polymer was pulled outward as a result of 
the dragging force of the solvents and thus the central 
void space emerged. The central cavity produced by 
the solvents was gradually filled with water due to the 
reduced internal pressure. Water escaped out of the cav-
ity during the drying process, ultimately forming hollow 
microspheres (Pushp, Myung, Hoo, 2007). 
Mechanism of gastroretention
When microspheres come in contact with gastric 
fluid, the gel formers, polysaccharides, and polymers hy-
drate to form a colloidal gel barrier that controls the rate of 
fluid penetration into the device and drug release. As the 
exterior surface of the dosage form dissolves, the gel layer 
is maintained by the hydration of the adjacent hydrocolloid 
layer. The air trapped by the swollen polymer lowers the 
density and confers buoyancy to the microspheres. How-
ever, a minimal gastric content is needed to allow proper 
achievement of buoyancy.
Adherence to the wall of the stomach will be pos-
sible during the emptying process in both the fed and the 
fasted state, assuming that the mucoadhesive properties 
of the particles have not been modified by the stomach 
contents, in particular, non-adherent mucus (Figure 4).
Process variables affecting physicochemical 
properties of hollow microspheres
Stirring rate
Srivastava, Ridhurkar and Wadhwa (2005) have 
studied the effects of the stirring rate on microsphere par-
ticle size. To observe the effect of agitation speed on the 
size of the resulting microspheres, formulations were pre-
pared at varying agitation speeds; 300 rpm, 500 rpm, 1000 
rpm. The size of the resulting microspheres decreased with 
increasing agitation, but the increase was not statistically 
significant. It may be inferred that the agitation speed in 
the study range was not able to break up the bulk of the 
polymer into finer droplets.
FIGURE 2 - Formulation of floating microspheres (Kawashima 
et al., 1991).
FIGURE 3 - SEM photographs of (a) outer surface of a 
microsphere, (b) inner surface of a broken half of a microsphere 
(Pushp, Myung, Hoo, 2007).
FIGURE 4 - Mechanism of gastroretention of floating 
microspheres having mucoadhesive polymer (Stanley, 2005).
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Temperature of preparation
Sato et al. (2003b) have studied optimum prepa-
ration temperature with respect to microsphere cavity 
formation. The solution drug and polymer were poured 
into an aqueous solution of polyvinyl alcohol at various 
temperatures, i.e., 20, 30, 40 and 50 ºC. They concluded 
that preparation at 20 or 30ºC provided porous micro-
spheres having higher porosity with a surface so rough as 
to crumble upon touching. Although the respective appar-
ent particle densities of the resulting hollow microspheres 
were low, both buoyancies were low, probably due to easy 
penetration of the dissolution medium through the porous 
surface. The roundness of hollow microspheres prepared at 
40 ºC was close to 1; moreover, surfaces were less rough 
than those of hollow microspheres prepared at 20 or 30 
ºC. Hollow microspheres prepared at 50 ºC exhibited no 
hollow nature; however, a single large depression occurred 
on the surface. The hollow microspheres possessed high 
apparent particle density and low buoyancy due to the 
absence of a cavity. Few traces of evaporation were ob-
served on the surface, which was attributable to the rapid 
evaporation of dichloromethane at temperatures beyond 
the boiling point (40.2 ºC). At 40 ºC, polymers and the 
drug were coprecipitated, and the shell was formed by the 
diffusion of ethanol into the aqueous solution and simulta-
neous evaporation of dichloromethane. In contrast, hollow 
microspheres prepared at 50 ºC demonstrated a single large 
depression on the surface, which was a consequence of the 
rapid evaporation of dichloromethane.
Plasticizers
Patil et al. (2009) have studied the effect of plasti-
cizer concentration on the surface of microspheres and 
on the release of the drug. They have found that the addi-
tion of plasticizer made the wall of material more elastic 
and flexible, so that it never got brittle or ruptured under 
pressure. It was also observed that the release of the drug 
increased significantly with the increase of plasticizer 
concentration.
Volume of aqueous phase
Jain et al. (2005) have studied the effect of vari-
ous volumes on the formation of hollow microspheres. 
Volumes of aqueous phase used were 200, 300, 400 and 
500 ml they observed that the potential advantage of us-
ing large volumes of the external aqueous phase was the 
reduction of the required stirring times. The solubility of 
dichloromethane in water is 1% w/v. Using a larger volume 
(400 to 500 ml), the diffusion of dichloromethane into the 
aqueous phase, and hence the solidification of particles, 
occurred faster, when compared to a volume of 200 ml.
Solvent ratio
The bridging liquid plays a key role in microsphere 
preparation. When a good solvent diffuses into the poor 
solvent, which causes the precipitation of the drug and 
the polymer, a bridge liquid must be present in order to 
maintain the spherical shape of the microsphere. Too small 
a volume of the bridging liquid can lead to irregularly 
shaped microspheres while too large a volume of bridging 
liquid could prevent the emulsion droplets from solidify-
ing. Therefore, the amount of dichloromethane needs to 
be carefully controlled (Hu et al., 2006).
The ratio of dichloromethane with ethanol also af-
fected the morphology of the microspheres and the best 
results with spherical shape were obtained when the ratio 
of ethanol to dichloromethane was 2:1 (Jain et al., 2005).
Amount of polymer and viscosity
Gattani, Kawtikwar and Sakarkar (2009) have stud-
ied the effect of polymer concentration on in vitro release 
of aceclofenac from floating microspheres. Increased den-
sity of the polymer matrix at higher concentrations results 
in increased diffusional pathlength. This may decrease the 
overall drug release from the polymer matrix. Further-
more, smaller microspheres are formed at a lower polymer 
concentration and have a larger surface area exposed to 
dissolution medium, giving rise to faster drug release.
Srivastava, Ridhurkar and Wadhwa (2005) prepared 
microspheres using a gradually increasing ethyl cellulose 
concentration in combination with a fixed concentration of 
hydroxy propyl methyl cellulose (HPMC) to assess the ef-
fect of polymer concentration on the size of microspheres. 
Mean particle size of the microspheres significantly 
increased with increasing ethyl cellulose. The viscosity 
of the medium increases at a higher polymer concentra-
tion, resulting in enhanced interfacial tension. Shearing 
efficiency is also diminished at higher viscosities. This 
results in the formation of larger particles.
When viscosity is increased, the yield of hollow 
microspheres is decreased, and mean diameter and drug 
loading amount are increased (Wei, Zhao, 2008). 
Baykara and Kiliçarslan (2003) have studied the 
effect of the drug-to-polymer ratio on the properties of 
verapamil HCl loaded microspheres. They found that 
the drug dissolution profile could be slowed down by 
increasing polymer amount in the formulations, and that 
particle size, surface characteristics of microspheres, and 
dissolution rate of verapamil could be modified through 
the variation of drug-to-polymer ratio.
Effect of solvents
Bornare et. al. (2009) have studied the effect of 
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various organic solvents on the formation of microspheres 
by the solvent evaporation method. Dichloromethane 
was employed as polar internal organic solvent phase for 
preparation of microspheres because it is a good solvent 
for most of polymers and drugs. However, it was observed 
that the microspheres obtained were not at all spherical in 
shape. To solve this problem, methanol was used, along 
with dichloromethane, in the preparation of microspheres. 
The microspheres so obtained were spherical, but lacked 
smooth texture. To avoid this problem, various solvents 
were critically screened on the basis of the boiling points, 
such as dichloromethane (39.75 oC), acetone (56.5 oC), 
methanol (64.7 oC) and ethanol (78.4 °C). It was observed 
that the boiling point increased from DCM to ethanol and 
so instead of DCM/methanol, ethanol was tried. Etha-
nol is a good solvent for most water-soluble drugs and 
water-insoluble polymers, and it is non-toxic. It remained 
dispersed as droplets in the oily phase, leading to the for-
mation of a stable emulsion. Ethanol may have worked 
because it has a high boiling point in relation to other or-
ganic solvents (dichloromethane, acetone, methanol etc.), 
which prevented immediate polymer precipitation. The 
researchers observed that the microspheres so obtained 
were completely spherical, with a smooth surface.
Emulsifier concentration
Nilkumhang and Basit (2009) have studied effect 
of emulsifier concentration on particle size. They found 
that the particle size and size distribution were increased 
when the surfactant concentration was reduced from 1% to 
0.25% (w/w). The role of the surfactant is to decrease the 
interfacial tension between the dispersed droplets and the 
continuous phase, as well as to protect the droplets from 
collision and coalescence. Low emulsifier concentrations 
may be insufficient to shield the entire droplet surface; 
droplets are more susceptible to collision and fusion. 
Also, at higher concentration of emulsifier, lower encap-
sulation efficiency and larger particle size were obtained, 
which suggests that the critical micelle concentration had 
been exceeded, which directly affected emulsion stabil-
ity. Hence, the optimum concentration of the emulsifier 
should be identified.
Release modifiers
Many drugs are not released in significant amount 
from this type of microparticles at the pH of gastric fluids 
(Lee, Park and Choi, 1999). So, there is a need for some 
hydrophilic polymers to be added into the formulation. 
Streubel, Siepmann and Bodmeier (2002) have developed 
a multiparticulate, floating drug delivery system consist-
ing of highly porous carrier material (foam powder), drug 
and polymer.
Various agents, such as HPMC, citric acid, PVP, 
PEG, etc., depending upon their properties, can be used 
to modify the drug release. These are also called as chan-
neling agents.
Karthikeyan et al. (2008) have studied the effect of 
different viscosity grades of HPMC on the drug release 
profile. He used three different grades of HPMC in com-
bination with various ratios of ethyl cellulose-to-HPMC. 
The various grades used were HPMC 15cp, HPMC K4M, 
and HPMC 100LV. The best release was found to be with 
the lowest viscosity grade of HPMC (HPMC 15cp) when 
compared to the other two viscosities (HPMC 100LV and 
HPMC K4M).
Sato et al. (2004b) have prepared floating micro-
spheres for riboflavin from Eudragit S100. In the urinary 
excretion study, they found that the total urinary excretion 
of riboflavin following administration of hollow micro-
spheres containing riboflavin was clearly lower than that 
of riboflavin powder, as very little riboflavin was released 
from the hollow microspheres into the dissolution medium 
(pH 1.2). Thus, hollow microspheres were prepared by 
mixing with a water-soluble polymer, HPMC, in Eudragit 
S100. The objective of these hollow microspheres was to 
increase the amount of riboflavin released from the hollow 
microspheres into the dissolution medium and to increase 
overall urinary excretion of riboflavin.
Characterization/evaluation of floating 
microspheres
Particle size
Size is measured using an optical microscope, and 
mean particle size is calculated by measuring 200–300 
particles with the help of a calibrated ocular micrometer.
Different sizes of microspheres and their distribution 
in each batch are measured by sieving in a mechanical 
shaker, using a nest of standard sieves (ASTM) and the 
shaking period of 15 minutes. Particle size distribution is 
determined and the mean particle size of microspheres is 
calculated by using the following formula (Badri et al., 
1999).
Mean particle size = ∑(mean particle size of the fraction× 
weight fraction)/∑(weight fraction)          (1)
Tapped density and compressibility index
The tapping method is used to determine the tapped 
density and percentage compressibility index, as follows 
(Sinko, 2006).
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                    (2)
 (3)
where V and Vo are the volumes of the sample after and 
before the standard tapping, respectively.
Surface morphology
The external and internal morphology of the mi-
crospheres is studied by scanning electron microscopy 
(SEM).
% Yield
 The yield was calculated from the following equa-
tion.
 (4)
Percentage of drug content / drug loading amount(%)
A fixed amount of microspheres containing a drug 
are dissolved in a suitable solvent such as ethanol, metha-
nol, etc. by ultrasonication. The solution is then filtered 
through a 5 µm membrane filter. Finally, drug concentra-
tion is determined by the UV, spectrophotometrically. 
Drug content is calculated according to following equa-
tion:
 (5)
Percentage of drug entrapment
The percentage of drug entrapment can be calculated 
by the following equation.
 (6)
Floating behavior
The floating test on the microspheres is carried out 
using the dissolution method II apparatus, specified in the 
USP XXII. The microspheres are spread over the surface 
of the dispersing medium (900 ml), which is agitated by 
a paddle rotated at 100 rpm. Disintegration test solution 
No. 1 (pH 1.2), containing Tween 20 (0.02%, w/v), was 
used as a dispersing medium to simulate gastric fluid. After 
agitation for a previously determined interval, the hollow 
microspheres that floated over the surface of medium and 
those that settled to the bottom of the flask were recov-
ered separately. After drying, each fraction of the hollow 
microspheres was weighed. The buoyancy of the hollow 
microspheres was represented by the following equation 
(Kawashima et al., 1991).
  
(7)
where Qf and Qs are the weights of the floating and settled 
hollow microspheres, respectively.
In vivo buoyancy
Jain, Agarwal and Jain (2006a) have studied stud-
ied the gastric retention time of floating microspheres by 
gamma scintigraphy. The in vivo transit behavior of the 
floating and non floating microspheres was monitored 
using 12 one-year-old male albino rabbits. These rabbits 
were divided into two groups, i.e., group I and group II. 
In order to standardize the conditions of GI motility, 
the animals were fasted for 12 hours prior to the com-
mencement of each experiment. Floating microspheres 
(100 mg) were orally administered in suspension form to 
the animals in group I and non-floating microspheres were 
administered to group II, followed by a sufficient volume 
of drinking water. The location of the formulation in the 
stomach was monitored by keeping the subjects in front 
of a gamma camera. In between the gamma scannings, 
the animals were freed and allowed to move and carry out 
normal activities, but were not allowed to ingest any food 
or water until the formulation had emptied the stomach 
completely.
Kawashima et al. (1991) prepared hollow micro-
spheres made with Eudragit S, containing barium sulfate 
as a contrast agent for the radiographical in vivo test. The 
study was carried out with two healthy male volunteers, 
free of detectable gastrointestinal diseases or disorders. 
Each subject, having fasted overnight, had a light Japanese 
breakfast (one rice ball and one cup of soup). After 30 
minutes, each subject ingested two hard-gelatin capsules 
packed with hollow microspheres (1000 mg), together 
with 100 ml of water. The intragastric behavior of the 
hollow microspheres after dosing was observed by taking 
a series of X-ray photographs at suitable intervals. Cui 
et al. (2008) and Sato et al. (2004a) had performed the 
same study on healthy human volunteers, using gamma 
scintigraphy.
In vitro release studies
In vitro dissolution studies can be carried out in 
a USP paddle type dissolution assembly. Microspheres 
equivalent to the drug dose are added to 900 ml of the 
dissolution medium and stirred at 100 rpm at 37 ± 0.5 °C. 
Samples are withdrawn at a specified time interval and 
analyzed by any suitable analytical method, such as UV 
spectroscopy or HPLC, etc.
Wei et al. (2008) used the same apparatus with the 
following modifications: the microspheres were intro-
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duced into a dialysis membrane bag with molecular weight 
cut off of 8000-12000. The test bag, which was tied and 
bound to the rotating paddle by a thread, was immersed in 
the dissolution medium; the rotating speed was 100 rpm.
In vivo studies
In vivo studies are generally conducted in healthy 
male albino rabbits weighing 2-2.5 kg. The animals are 
fasted for 24 hours before the experiments; however, 
they are given free access to food and water during the 
experiments. Blood samples (2 mL) are collected from 
the marginal ear vein into heparinized centrifuge at an ap-
propriate time interval (Wei, Zhao, 2008; Joseph, Lakshmi, 
Jayakrishnan, 2002).
Sato et al. (2003a) has carried out an in vivo study in 
healthy human volunteers. The pharmacokinetic param-
eters were determined by the analysis of urinary excretion 
data.
Applications of floating microspheres
1. Floating microspheres can be used as carriers for 
drugs with so-called absorption windows, these substanc-
es, for example antiviral, antifungal and antibiotic agents 
(sulphonamides, quinolones, penicillins, cephalosporins, 
aminoglycosides and tetracyclines) are taken up only from 
very specific sites of the GI mucosa. 
2. Hollow microspheres of non-steroidal anti-in-
flammatory drugs are very effective for controlled release, 
and reduce the major side effect of gastric irritation. For 
example, floating microspheres of indomethacin are quite 
beneficial for rheumatic patients. 
3. Floating microspheres are especially effective in 
the delivery of sparingly soluble and insoluble drugs. It is 
known that as the solubility of a drug decreases, the time 
available for drug dissolution becomes less adequate, and 
thus transit time becomes a significant factor affecting 
drug absorption. For weakly basic drugs that are poorly 
soluble at an alkaline pH, hollow microspheres may avoid 
the risk of solubility becoming the rate-limiting step in re-
lease, by restricting such drugs to the stomach. Positioned 
gastric release is useful for drugs efficiently absorbed 
through the stomach, such as verapamil hydrochloride. 
The gastroretentive floating microspheres will beneficially 
alter the absorption profile of the active agent, thus enhanc-
ing its bioavailability. 
4. Hollow microspheres can greatly improve the 
pharmacotherapy of the stomach through local drug re-
lease, leading to high drug concentrations at the gastric 
mucosa, thus eradicating Helicobacter pylori from the 
sub-mucosal tissue of the stomach and making it pos-
sible to treat stomach and duodenal ulcers, gastritis and 
oesophagitis (Umamaheshwari et al., 2003).
CONCLUSION
Drug absorption in the gastrointestinal tract is a 
highly variable procedure and prolonging gastric retention 
of the dosage form extends the time for drug absorption. 
Floating controlled drug delivery systems are employed 
to solve this problem. Floating microspheres have been 
showing high potential for gastroretention and provide an 
efficient means of enhancing bioavailability and control-
ling the release of many drugs.
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